跳转至内容
Merck
CN

A9730

Adefovir dipivoxil

别名:

9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H32N5O8P
化学文摘社编号:
分子量:
501.47
NACRES:
NA.76
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

WOZSCQDILHKSGG-UHFFFAOYSA-N

SMILES string

CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C

InChI

1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)

biological source

synthetic

assay

≥98% (HPLC)

form

powder

solubility

ethanol: 50 mg/mL

antibiotic activity spectrum

viruses

mode of action

enzyme | inhibits

storage temp.

−20°C

Quality Level

Biochem/physiol Actions

Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase. It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification. Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1). Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages .

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Julien Delmas et al.
Antimicrobial agents and chemotherapy, 46(2), 425-433 (2002-01-18)
The elimination of viral covalently closed circular DNA (CCC DNA) from the nucleus of infected hepatocytes is an obstacle to achieving sustained viral clearance during antiviral therapy of chronic hepatitis B virus (HBV) infection. The aim of our study was
A Takeda et al.
Journal of viral hepatitis, 14(2), 75-88 (2007-01-25)
Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively. The aim of this systematic review and economic evaluation was to assess the clinical effectiveness and
F Stelma et al.
Journal of viral hepatitis, 24(12), 1107-1113 (2017-06-21)
Combining peginterferon-alfa-2a (pegIFN) with a nucleotide analogue can result in higher rates of HBsAg loss than either therapy given alone. Here, we investigated the durability of the response to combination therapy in chronic hepatitis B (CHB) patients after 5 years of
Baek Gyu Jun et al.
PloS one, 13(7), e0201316-e0201316 (2018-07-31)
Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
Yuequan Shen, Natalia L. Zhukovskaya, et. Al
Proceedings of the National Academy of Sciences of the USA, 101, 3234-3247 (2004)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持